Corporate Profile
Taxus Cardium Pharmaceuticals is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of Cardiac Microvascular Insufficiency due to advancing coronary artery disease, and Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics.
Stock Quote
CRXM (Common)
ExchangeOTC BB (US Dollar)
Change (%)-0.00 (0.00%)
Data as of 02/23/18 12:45 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000CRXM
Recent News
01/08/18Taxus Cardium Announces Name Change To Gene BiotherapeuticsPrinter Friendly Version
06/13/17Excellagen® Receives USPTO Notice Of Allowance For A New Patent Application Covering Blood Platelet Activation & Endogeneous Growth Factor Release For Wound Repair And Tissue RegenerationPrinter Friendly Version
06/12/17Angionetics To Present At Marcum 2017 MicroCap conference In New York CityPrinter Friendly Version
06/05/17Angionetics To Present At Globalization Of Research And Industrialization Of Bio-Medicine Summit 2017 In Shenzhen, ChinaPrinter Friendly Version
Primary IR Contact
Shareholder Services
Corporate Communications/Investor Relations
11750 Sorrento Valley Road
San Diego, CA 92121

Phone: 858-436-1018

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.